Cuprina Holdings updates on three studies developing collagen peptides from bullfrog skin for medical and cosmetic applications.
Quiver AI Summary
Cuprina Holdings (Cayman) Limited, a Singapore-based biomedical and biotechnology company, announced progress on three collaborative studies focused on developing collagen peptides from American bullfrog skin for use in medical, pharmaceutical, and cosmetic applications. The company’s first study with Republic Polytechnic has resulted in the ability to generate bullfrog collagen peptides for potential cosmeceutical use, such as skin moisturization. A second study, in collaboration with the National University of Singapore, is exploring the use of these peptides for 3D printable wound care dressings, while a third study with the Singapore Institute of Technology aims to produce a superior powdered form of these peptides. Cuprina's CEO expressed optimism about the commercial prospects of bullfrog-derived collagen, especially given its advantages over traditional sources. The global collagen peptides market is expected to grow significantly, reflecting increasing demand across various sectors.
Potential Positives
- Cuprina is collaborating with three prominent research institutes, highlighting its commitment to innovation and credibility in the biomedical and biotechnology fields.
- The studies focus on developing bullfrog collagen peptides, which have demonstrated superior properties over traditional bovine sources, potentially leading to more effective medical and cosmetic products.
- The anticipated growth of the global collagen peptides market provides Cuprina with promising commercial opportunities in various sectors, including medical and cosmetics.
- Successful testing of bullfrog collagen in wound care applications could significantly enhance product offerings and market competitiveness for Cuprina.
Potential Negatives
- Cuprina Holdings has faced inherent risks and uncertainties associated with its reliance on the successful outcomes of ongoing studies, which could significantly impact future commercialization efforts.
- The press release highlights that results of Cuprina's studies, particularly in the development of innovative products, remain uncertain and contingent upon successful testing, which may affect investor confidence.
- There is no mention of any current partnerships or contracts for the commercialization of their products, which could indicate a lack of established market presence or demand for their developments.
FAQ
What is Cuprina Holdings focused on developing?
Cuprina Holdings specializes in products for managing chronic wounds, infertility, and cosmeceuticals in the health and beauty sectors.
What innovative material is Cuprina using in its studies?
Cuprina is utilizing collagen peptide molecules derived from American bullfrog skin for various medical and cosmetic applications.
Where is Cuprina conducting its collaborative studies?
Cuprina is collaborating with research institutes in Singapore, including Republic Polytechnic and the National University of Singapore.
What potential benefits do bullfrog collagen peptides offer?
Bullfrog collagen peptides exhibit superior biocompatibility and efficacy, showing higher wound closure rates compared to traditional sources like bovine collagen.
What is the forecast for the global collagen peptides market?
The global collagen peptides market is projected to grow from US$699 million in 2023 to US$922 million by 2028, at a CAGR of 5.7%.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“ Cuprina ” or “the Company ”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed at helping Cuprina and these institutes jointly produce collagen peptide molecules derived from American bullfrog skin. These peptides, as well as their short chain variants, are widely considered to be useful in the manufacture of an array of medical, pharmaceutical, nutraceutical and cosmetic products.
The first study was performed pursuant to a consultancy proposal (“CP”) signed in February 2024 with Republic Polytechnic (“RP”), an institute of higher learning under the purview of the Ministry of Education in Singapore. Under this agreement, Cuprina and RP collaborated to generate bullfrog collagen peptides that can be sold as is or separated and sold as individual peptide fragments.
Since the completion of this consultancy proposal in February 2025, Cuprina has identified a method to generate a series of these peptides that can potentially be used for cosmeceutical applications including skin moisturization, collagen remodeling, and other commercial applications. Cuprina is currently in the process of pursuing marketing opportunities for these peptides with a number of cosmeceutical entities.
Cuprina’s second study, a research collaboration agreement (“RCA”) which commenced in October 2024, was signed with the Institute for Health Innovation and Technology at the National University of Singapore, Singapore’s flagship university that offers a global approach to education, research and entrepreneurship. Joint research from this agreement is aimed at exploring the viability of using bullfrog collagen peptides in the production of 3D printable wound care dressings for a variety of research and clinical applications. Funding for this research is supported by the National Additive Manufacturing Innovation Cluster Singapore, a national platform hosted by the Agency for Science, Technology and Research.
Currently, Cuprina is performing testing aimed at measuring the effect of integrating bullfrog collagen into the structure of microneedling patches, which contain tiny needles that allow active ingredients to penetrate deeper into the skin and enhance wound healing. If these tests prove successful, these new patches could help to control the inflammation that typically impedes wound healing.
The third study is an RCA with the Singapore Institute of Technology, an autonomous university in Singapore, that commenced in January 2025. Both parties endeavor to produce a superior powdered form of bullfrog collagen peptides that can be sold as is or as individual peptide fragments suitable for cosmeceuticals.
In vivo and in vitro tests have demonstrated that bullfrog skins generate a pristine, triple helix collagen molecule that possesses numerous beneficial properties including superior biocompatibility and thermal stability compared to bovine and other collagen sources. In addition, published studies have reported that bullfrog-derived collagen produced 90 percent wound closure in 24 hours versus 34 percent for bovine collagen.
“We are very gratified by our collaborations with these three leading research institutes,” said Cuprina Chief Executive Officer David Quek. “I am optimistic that our joint efforts will lead to additional productive commercial applications for bullfrog-derived collagen peptides. Given the demonstrated advantages of bullfrog collagen, we believe this market has significant potential for worldwide growth.”
According to research firm MarketsandMarkets.com, the global collagen peptides market is expected to grow from US$699 million in 2023 to US$922 million in 2028, a CAGR of 5.7 percent. 1 As per the firm, “The value of collagen peptides has significantly risen due to its increased utilization in various sectors such as medical, cosmetics, food, and pharmaceutical applications. This growth is further driven by the growing awareness of consumer health in emerging markets like Asia Pacific, Middle East, Africa, and South America.”
About Cuprina Holdings (Cayman) Limited
Cuprina is a Singapore-based biomedical and biotechnology company dedicated to the development and commercialization of innovative products for the management of chronic wounds and infertility, as well as operating in the health and beauty sectors. The Company’s expertise in biomedical research allows it to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://www.cuprina.com .
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email:
[email protected]
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:
[email protected]
1 MarketsandMarkets Research Private Ltd (2023). Collagen Peptides Market by Source (Bovine, Porcine, Marine & Poultry), Application (Food & Beverages, Nutritional Products, Cosmetics & Personal Care Products, Pharmaceuticals), Form (Dry, Liquid) and Region - Global Forecast to 2028.
